Navigation Links
Vermillion Reports Third Quarter 2013 Results
Date:11/14/2013

ion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Forward-Looking Statement
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding Vermillion's expected cash outlay and Vermillion's ability to regain traction in reimbursement. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
3. Vermillion Sets Third Quarter 2013 Conference Call for Thursday, November 14, 2013
4. Vermillion Appoints Dr. Eric Varma to its Board of Directors
5. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
6. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
7. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
8. Vermillion Reports Fourth Quarter and Full Year 2012 Results
9. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
10. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
11. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or ... cloud-based platform, exchange, and big data solutions in ... launched its mobile app for Healthcare One Pass, ushering ... mobile devices. The Company jointly hosted the launch ceremony ... and Shenzhen News Net.   The mobile app ...
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... EDISON, N.J., Dec. 7 Q-Med AB and Oceana Therapeutics, Inc. ... primary endpoints for the treatment of fecal incontinence. , Q-Med AB ... the FDA during the first quarter of 2010 based on the ... result of years of hard work as we developed a product ...
... , SAN DIEGO, Dec. 7 CareFusion (NYSE: ... six new Pyxis® medication management products at the 44th American ... Exhibition Dec. 6 -10 in Las Vegas. , CareFusion is ... Pyxis products rank number one in user satisfaction ratings by ...
Cached Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... patient advocate, will be recognized by the White House as a “Champion of ... newly-launched President’s Precision Medicine Initiative, the Champions of Change program recognizes Gleason and ...
(Date:7/6/2015)... London, UK (PRWEB) , ... July 07, 2015 ... ... segments in the in vitro universe. Increasing incidence of AIDS, advances in the ... the key growth driving forces. Recent advances in detection technologies and genetic engineering ...
(Date:7/6/2015)... ... July 06, 2015 , ... “ TapGlance ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this interior design app helps users visualize what rooms will look like before they ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Shortly after ... Liens , the leading network of doctors working on a lien basis. Dr. ... on Liens. , The daughter of two Cambodian refugees, Dr. Lim suffered with back ...
(Date:7/6/2015)... ... 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value ... a CAGR of over 3.2 percent in the years to come to hit the ... spurred by an anticipated launch of a number of promising pipeline candidates and an ...
Breaking Medicine News(10 mins):Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2
... that the antipsychotic drug, clozapine has some very concerning ... available. ,"Clozapine is the last hope for ... study suggests that patients who need the most effective ... said J. Steven Lamberti, the lead author of the ...
... Weight loss surgery has more benefits that simply reducing the ... at the McGill University// . ,The researchers ... The study followed these people from 1986 to 2002. All ... compared with 5,700 people who did not undergo such surgery. ...
... with a hit in the head with the ball. While ... dizzy and queasy// you often just continue playing. The question ... signs of concussion—one of the least understood sports injuries, says ... of Indianapolis. “People assume a concussion means you’re unconscious but ...
... all the popular opinion by saying that beer is ... to all the beer lovers. ,Charles Bamforth, ... of California at Davis and an Anheuser-Busch endowed professor, ... valuable B vitamins, such as B12, folic acid and ...
... World Food Programme (WFP) announced on Wednesday that as ... acute food shortage in Southern Africa. //WFP executive director ... recent years, there was a distribution problem. ... to eat," he said. "Food and good nutrition are ...
... Degeneration (AMD) is higher among the people who smoke ... ,Current cigarette smoking was associated with a fivefold ... associated with a twofold higher risk of AMD. The ... higher risk of AMD, compared with non-smokers with the ...
Cached Medicine News:Health News:Beer is More Healthier Than Wine 2Health News:Cigarette Smoking and High Body Mass Index Increase the Risk of AMD 2
... Captique is a non-animal stabilized ... newest HA filler to enter the ... correction of moderate to severe facial ... folds). Captique is injected just under ...
... Radiesse brings you into the new ... can now offer your patients immediate, long-term ... and flexibility. This injectable filler offers superior ... cosmetic and reconstructive treatments. Long-lasting, Radiesse saves ...
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... clinically proven to reduce the appearance of ... formula combines Retinol, the purest form of ... It works deep within skin's surface to ... appearance. Fast absorbing, it has a fresh, ...
Medicine Products: